Armenia - Tiếng Anh - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome production - salbutamol (salbutamol sulfate) - solution pressurised inhalation - 100mcg/dose

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 0.6 mg/ml (equivalent: salbutamol, qty 0.5 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sulfuric acid; water for injections - indications as at 3rd december 2002: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

dispensing solutions inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 108 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. teratogenic effects pregnancy category c. there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relations

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 0.48 mg/ml equivalent to 0.4 mg/ml salbutamol (or 2 mg salbutamol per 5 ml);   - syrup - 2 mg/5ml - active: salbutamol sulfate 0.48 mg/ml equivalent to 0.4 mg/ml salbutamol (or 2 mg salbutamol per 5 ml)   excipient: citric acid monohydrate hypromellose orange flavour 17-42-8187 purified water saccharin sodium sodium benzoate sodium chloride sodium citrate dihydrate - ventolin syrup is indicated for the treatment or prevention of bronchospasm. it provides short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment. ventolin syrup is suitable oral therapy for children or those adults who prefer liquid medicines.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 2.4 mg/ml (equivalent: salbutamol, qty 2 mg/ml) - inhalation - excipient ingredients: sodium chloride; sulfuric acid; water for injections - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 1.2 mg/ml (equivalent: salbutamol, qty 1 mg/ml) - inhalation - excipient ingredients: sodium chloride; water for injections; sulfuric acid - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage);   - solution for inhalation - 2.5mg/2.5ml - active: salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage);   - solution for inhalation - 5mg/2.5ml - active: salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salbutamol - solution for injection - 500 microgram(s)/millilitre - selective beta-2-adrenoreceptor agonists; salbutamol

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - salbutamol sulfate - solution for infusion - 1mg/1ml